Nanosphere Achieves CE-IVD Marks for Three Tests, Launches in Europe | GenomeWeb

By Justin Petrone

Nanosphere this week announced that it has received CE-IVD marks for three of its array-based tests and has "commenced distribution" in several European markets.

The Northbrook, Ill.-based molecular diagnostics firm achieved CE-IVD marks for its Respiratory Virus Plus Nucleic Acid Test, its CYP 2C19 Nucleic Acid Test for clopidogrel metabolism, and its Warfarin Metabolism Nucleic Acid Test, all of which run on its Verigene platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.